Long acting meds in the pipeline?
Dec 23, 2006
Dr: Hello. Could you name a few for the long acting medicines that you medtioned in a prior posting.
Thanks for the service provided by yourself and the other doctors here. Lorcan in Ireland
Response from Dr. Pierone
Hello, and thanks for posting.
There are some long-acting medications in the pipeline. Roche may be trying to reformulate Fuzeon as a once a week medication. If this effort is successful it would represent a vast improvement over the twice daily injection which is currently used.
TNX-355 is a monoclonal antibody which has been in trials for quite a while and is administered by the intravenous route and has antiviral activity that persists for several weeks. PRO-140 is another monoclonal antibody with a prolonged action that is entering trials.
Some of the medications that we currently use actually have a very long half life, and could be dosed less frequently, but we don't use them this way currently. For example, Sustiva stays around in the bloodstream for over a week after the last dose. This prolonged persistence is probably one the reasons that resistance may be more likely to develop in the face of suboptimal adherence (since the half-lives of the nukes are shorter and effective monotherapy results). This may be less of an issue with Atripla or Truvada/Sustiva since Viread and Emtriva have a longer duration of action than older agents.
In any case, the improved pharmacokinetics of newer agents will hopefully translate into better clinical outcomes for people living with HIV infection.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.